Log In
BCIQ
Print this Print this
 

CPC-252

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionCombination of Exelon rivastigmine, an acetylcholinesterase (AChE) inhibitor, and an undisclosed pharmaceutical
Molecular Target
Mechanism of ActionAcetylcholinesterase (AChE) inhibitor
Therapeutic ModalitySmall molecule: Combination

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$125.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/22/2016

Undisclosed

$125.0M

Undisclosed

Get a free BioCentury trial today